Exenatide vs Tirzepatide
Research Verdict
Tirzepatide is the stronger research reference for the stated comparison criteria. Tirzepatide: SURMOUNT Phase 3 (22.5% weight loss), SURPASS Phase 3 for T2DM, FDA approved (Mounjaro/Zepbound).
Quick Answers
Which is better, Exenatide or Tirzepatide?
Tirzepatide is the stronger research reference for the stated comparison criteria. Tirzepatide: SURMOUNT Phase 3 (22.5% weight loss), SURPASS Phase 3 for T2DM, FDA approved (Mounjaro/Zepbound).
What is the key difference between Exenatide and Tirzepatide?
Tirzepatide adds GIP receptor agonism to GLP-1, producing substantially greater metabolic effects; exenatide is a pure GLP-1RA - the 15-20 percentage point weight loss gap is among the largest between approved agents in the same class.
Evidence Comparison
Tirzepatide: SURMOUNT Phase 3 (22.5% weight loss), SURPASS Phase 3 for T2DM, FDA approved (Mounjaro/Zepbound). Exenatide: first-in-class GLP-1RA, 3-5% weight loss, EXSCEL neutral CVOT. Tirzepatide represents a generational improvement.
Evidence Context Favoring Exenatide
Cost-driven contexts, historical first-in-class comparisons, or settings where generic GLP-1RA availability is relevant.
Evidence Context Favoring Tirzepatide
Maximum weight loss or glycemic efficacy is the research endpoint - tirzepatide is unambiguously superior.
Side-by-Side Snapshot
| Evidence grade | Exenatide: Level A Tirzepatide: Level A |
|---|---|
| Research status | Exenatide: FDA Approved Tirzepatide: FDA Approved |
| Primary category | Exenatide: Weight Loss & Metabolic Tirzepatide: Weight Loss & Metabolic |
| Cited studies | Exenatide: 3 Tirzepatide: 5 |